KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Other Non Operating Income (2016 - 2025)

Sarepta Therapeutics has reported Other Non Operating Income over the past 15 years, most recently at -$121.7 million for Q4 2025.

  • For Q4 2025, Other Non Operating Income fell 1309.88% year-over-year to -$121.7 million; the TTM value through Dec 2025 reached -$28.2 million, down 166.07%, while the annual FY2025 figure was $16.9 million, 60.5% down from the prior year.
  • Other Non Operating Income for Q4 2025 was -$121.7 million at Sarepta Therapeutics, down from $138.6 million in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $387.3 million in Q1 2023 and troughed at -$121.7 million in Q4 2025.
  • A 5-year average of $33.7 million and a median of $6.5 million in 2024 define the central range for Other Non Operating Income.
  • Biggest five-year swings in Other Non Operating Income: soared 31469.43% in 2022 and later crashed 1370.55% in 2025.
  • Year by year, Other Non Operating Income stood at $656000.0 in 2021, then skyrocketed by 742.53% to $5.5 million in 2022, then skyrocketed by 6907.42% to $387.3 million in 2023, then crashed by 97.4% to $10.1 million in 2024, then plummeted by 1309.88% to -$121.7 million in 2025.
  • Business Quant data shows Other Non Operating Income for SRPT at -$121.7 million in Q4 2025, $138.6 million in Q3 2025, and $38.1 million in Q2 2025.